Catalogue
Articles
RSS feedX
Search Filters
Format
Subjects
Library Location
Language
Publication DateCirculation, ISSN 0009-7322, 05/1999, Volume 99, Issue 19, pp. 2530 - 2536
Background-Cardiopulmonary bypass (CPB) induces platelet activation with release of platelet factor 4 (PF4), and patients are exposed to high doses of heparin...
Cardiopulmonary bypass | Antibodies | Heparin | Platelets | SURGERY | CARDIAC & CARDIOVASCULAR SYSTEMS | THROMBOSIS | FORM | COMPLEXES | SERA | RECEPTOR | POLYMORPHISM | FC-GAMMA-RIIA | platelets | heparin | MUTATION | cardiopulmonary bypass | PERIPHERAL VASCULAR DISEASE | antibodies | DEPENDENT ANTIBODIES | HEMATOLOGY | Humans | Middle Aged | Thrombocytopenia - immunology | Platelet Factor 4 - immunology | Postoperative Complications - prevention & control | Heparin, Low-Molecular-Weight - adverse effects | Heparin - therapeutic use | Male | Thrombocytopenia - chemically induced | Cardiopulmonary Bypass | Heparin - adverse effects | Heparin, Low-Molecular-Weight - therapeutic use | Heparin - immunology | Adolescent | Aged, 80 and over | Antibodies - immunology | Adult | Antibodies - blood | Female | Aged
Cardiopulmonary bypass | Antibodies | Heparin | Platelets | SURGERY | CARDIAC & CARDIOVASCULAR SYSTEMS | THROMBOSIS | FORM | COMPLEXES | SERA | RECEPTOR | POLYMORPHISM | FC-GAMMA-RIIA | platelets | heparin | MUTATION | cardiopulmonary bypass | PERIPHERAL VASCULAR DISEASE | antibodies | DEPENDENT ANTIBODIES | HEMATOLOGY | Humans | Middle Aged | Thrombocytopenia - immunology | Platelet Factor 4 - immunology | Postoperative Complications - prevention & control | Heparin, Low-Molecular-Weight - adverse effects | Heparin - therapeutic use | Male | Thrombocytopenia - chemically induced | Cardiopulmonary Bypass | Heparin - adverse effects | Heparin, Low-Molecular-Weight - therapeutic use | Heparin - immunology | Adolescent | Aged, 80 and over | Antibodies - immunology | Adult | Antibodies - blood | Female | Aged
Journal Article
Details 
Digital rights
Loading RightsThe New England Journal of Medicine, ISSN 0028-4793, 05/1991, Volume 324, Issue 22, pp. 1565 - 1574
HEPARIN was discovered in 1916 by McLean, 1 who as a medical student was looking for a coagulant in the liver. In 1939, Brinkhous and associates 2 demonstrated...
MEDICINE, GENERAL & INTERNAL | CONTINUOUS INTRAVENOUS HEPARIN | TISSUE PLASMINOGEN-ACTIVATOR | MOLECULAR WEIGHT HEPARIN | LOW-DOSE HEPARIN | ACUTE MYOCARDIAL-INFARCTION | VENOUS THROMBOSIS | SUBCUTANEOUS HEPARIN | DEEP-VEIN THROMBOSIS | ANTITHROMBIN-III | PARTIAL THROMBOPLASTIN TIME | Pregnancy | Humans | Coronary Disease - drug therapy | Female | Heparin - therapeutic use | Thromboembolism - drug therapy | Heparin - adverse effects | Adverse and side effects | Health aspects | Heparin | Drug therapy | Anticoagulants | Plasma
MEDICINE, GENERAL & INTERNAL | CONTINUOUS INTRAVENOUS HEPARIN | TISSUE PLASMINOGEN-ACTIVATOR | MOLECULAR WEIGHT HEPARIN | LOW-DOSE HEPARIN | ACUTE MYOCARDIAL-INFARCTION | VENOUS THROMBOSIS | SUBCUTANEOUS HEPARIN | DEEP-VEIN THROMBOSIS | ANTITHROMBIN-III | PARTIAL THROMBOPLASTIN TIME | Pregnancy | Humans | Coronary Disease - drug therapy | Female | Heparin - therapeutic use | Thromboembolism - drug therapy | Heparin - adverse effects | Adverse and side effects | Health aspects | Heparin | Drug therapy | Anticoagulants | Plasma
Journal Article
Details
Digital rights
Loading RightsThrombosis and Haemostasis, ISSN 0340-6245, 07/2009, Volume 102, Issue 1, pp. 62 - 68
We have developed an antithrombin-heparin covalent complex (ATH) which inhibits coagulation enzymes by two mechanisms: directly, or by catalytic activation of...
heparin | catalysis | anticoagulant | thrombelastography | Antithrombin-heparin complex | Anticoagulant | Thrombelastography | Catalysis | Heparin | COMPLEX | THROMBOELASTOGRAPHY | CARDIOPULMONARY BYPASS | WHOLE-BLOOD | THROMBIN GENERATION | PATHWAY INHIBITOR | PLASMA | COAGULATION | PERIPHERAL VASCULAR DISEASE | RATE ENHANCEMENT | HEMATOLOGY | TISSUE FACTOR | Plasma | Heparin, Low-Molecular-Weight - pharmacology | Anticoagulants - metabolism | Antithrombins - metabolism | Humans | Thrombelastography - drug effects | Antithrombins - pharmacology | Dose-Response Relationship, Drug | Blood Coagulation - drug effects | Anticoagulants - pharmacology | Fibrinogen - metabolism | Heparin, Low-Molecular-Weight - metabolism
heparin | catalysis | anticoagulant | thrombelastography | Antithrombin-heparin complex | Anticoagulant | Thrombelastography | Catalysis | Heparin | COMPLEX | THROMBOELASTOGRAPHY | CARDIOPULMONARY BYPASS | WHOLE-BLOOD | THROMBIN GENERATION | PATHWAY INHIBITOR | PLASMA | COAGULATION | PERIPHERAL VASCULAR DISEASE | RATE ENHANCEMENT | HEMATOLOGY | TISSUE FACTOR | Plasma | Heparin, Low-Molecular-Weight - pharmacology | Anticoagulants - metabolism | Antithrombins - metabolism | Humans | Thrombelastography - drug effects | Antithrombins - pharmacology | Dose-Response Relationship, Drug | Blood Coagulation - drug effects | Anticoagulants - pharmacology | Fibrinogen - metabolism | Heparin, Low-Molecular-Weight - metabolism
Journal Article
Details
Digital rights
Loading RightsCochrane Database of Systematic Reviews, ISSN 1469-493X, 04/2017, Volume 2017, Issue 4, p. CD007557
Background Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction presenting as a prothrombotic disorder related to antibody-mediated platelet...
Thrombosis [etiology; prevention & control] | ED AMERICAN-COLLEGE | Thrombocytopenia [chemically induced, complications | RISK-FACTORS | Humans | Heparin [administration & dosage; adverse effects] | DEEP-VEIN THROMBOSIS | prevention & control | PATIENTS ANTITHROMBOTIC THERAPY | ANTIBODY-FORMATION | Postoperative Complications [chemically induced | Randomized Controlled Trials as Topic | Heparin, Low-Molecular-Weight [administration & dosage; adverse effects] | MEDICINE, GENERAL & INTERNAL | Anticoagulants [administration & dosage; adverse effects] | VENOUS THROMBOEMBOLISM | PORCINE HEPARIN | HIP-REPLACEMENT | HEMORRHAGIC COMPLICATIONS | CRITICALLY-ILL PATIENTS | Venous Thrombosis [etiology; prevention & control] | Anticoagulants - administration & dosage | Postoperative Complications - prevention & control | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Surgical Procedures, Operative - statistics & numerical data | Thrombocytopenia - chemically induced | Anticoagulants - adverse effects | Heparin - adverse effects | Thrombocytopenia - complications | Venous Thrombosis - etiology | Numbers Needed To Treat | Thrombosis - etiology | Thrombocytopenia - prevention & control | Venous Thrombosis - prevention & control | Heparin, Low-Molecular-Weight - administration & dosage | Thrombosis - prevention & control | Postoperative Complications - chemically induced
Thrombosis [etiology; prevention & control] | ED AMERICAN-COLLEGE | Thrombocytopenia [chemically induced, complications | RISK-FACTORS | Humans | Heparin [administration & dosage; adverse effects] | DEEP-VEIN THROMBOSIS | prevention & control | PATIENTS ANTITHROMBOTIC THERAPY | ANTIBODY-FORMATION | Postoperative Complications [chemically induced | Randomized Controlled Trials as Topic | Heparin, Low-Molecular-Weight [administration & dosage; adverse effects] | MEDICINE, GENERAL & INTERNAL | Anticoagulants [administration & dosage; adverse effects] | VENOUS THROMBOEMBOLISM | PORCINE HEPARIN | HIP-REPLACEMENT | HEMORRHAGIC COMPLICATIONS | CRITICALLY-ILL PATIENTS | Venous Thrombosis [etiology; prevention & control] | Anticoagulants - administration & dosage | Postoperative Complications - prevention & control | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Surgical Procedures, Operative - statistics & numerical data | Thrombocytopenia - chemically induced | Anticoagulants - adverse effects | Heparin - adverse effects | Thrombocytopenia - complications | Venous Thrombosis - etiology | Numbers Needed To Treat | Thrombosis - etiology | Thrombocytopenia - prevention & control | Venous Thrombosis - prevention & control | Heparin, Low-Molecular-Weight - administration & dosage | Thrombosis - prevention & control | Postoperative Complications - chemically induced
Journal Article
Details
Digital rights
Loading RightsJournal of Thrombosis and Haemostasis, ISSN 1538-7933, 07/2007, Volume 5, Issue 7, pp. 1373 - 1379
Background: Heparin‐induced thrombocytopenia (HIT) is a severe disease that is often difficult to diagnose. A clinical scoring system, the ‘4Ts’ score, has...
heparin | 4Ts score | thrombocytopenia | particle gel immunoassay | Thrombocytopenia | Heparin | Particle gel immunoassay | SURGERY | MANAGEMENT | THROMBOSIS | LIKELIHOOD RATIOS | CLINICAL-FEATURES | INDUCED ANTIBODIES | MOLECULAR-WEIGHT HEPARIN | PERIPHERAL VASCULAR DISEASE | PLATELET-AGGREGATION TEST | DEPENDENT ANTIBODIES | HEMATOLOGY | UNFRACTIONATED HEPARIN | Drug Hypersensitivity - blood | Predictive Value of Tests | Prospective Studies | Immunoglobulin G - blood | Autoantibodies - blood | Humans | Middle Aged | Platelet Factor 4 - immunology | Male | Antigen-Antibody Complex - blood | Heparin - adverse effects | Purpura, Thrombocytopenic, Idiopathic - blood | Purpura, Thrombocytopenic, Idiopathic - etiology | Purpura, Thrombocytopenic, Idiopathic - immunology | Sensitivity and Specificity | Aged, 80 and over | Drug Hypersensitivity - diagnosis | Immunoassay - methods | Immunoassay - statistics & numerical data | Adult | Female | Drug Hypersensitivity - etiology | Heparin - immunology | Purpura, Thrombocytopenic, Idiopathic - diagnosis | Drug Hypersensitivity - immunology | Adolescent | Aged | Platelet Factor 4 - metabolism | Anticoagulants (Medicine) | Diagnosis | Analysis
heparin | 4Ts score | thrombocytopenia | particle gel immunoassay | Thrombocytopenia | Heparin | Particle gel immunoassay | SURGERY | MANAGEMENT | THROMBOSIS | LIKELIHOOD RATIOS | CLINICAL-FEATURES | INDUCED ANTIBODIES | MOLECULAR-WEIGHT HEPARIN | PERIPHERAL VASCULAR DISEASE | PLATELET-AGGREGATION TEST | DEPENDENT ANTIBODIES | HEMATOLOGY | UNFRACTIONATED HEPARIN | Drug Hypersensitivity - blood | Predictive Value of Tests | Prospective Studies | Immunoglobulin G - blood | Autoantibodies - blood | Humans | Middle Aged | Platelet Factor 4 - immunology | Male | Antigen-Antibody Complex - blood | Heparin - adverse effects | Purpura, Thrombocytopenic, Idiopathic - blood | Purpura, Thrombocytopenic, Idiopathic - etiology | Purpura, Thrombocytopenic, Idiopathic - immunology | Sensitivity and Specificity | Aged, 80 and over | Drug Hypersensitivity - diagnosis | Immunoassay - methods | Immunoassay - statistics & numerical data | Adult | Female | Drug Hypersensitivity - etiology | Heparin - immunology | Purpura, Thrombocytopenic, Idiopathic - diagnosis | Drug Hypersensitivity - immunology | Adolescent | Aged | Platelet Factor 4 - metabolism | Anticoagulants (Medicine) | Diagnosis | Analysis
Journal Article
Details
Digital rights
Loading RightsThe New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 252 - 261
HIT is characterized by a platelet-count fall of more than 50% at 5 to 10 days after the start of heparin and hypercoagulability. Platelet factor 4–heparin...
ANTIBODIES | MEDICINE, GENERAL & INTERNAL | IN-VITRO | ACTIVATION | CONFORMATIONAL-CHANGES | FONDAPARINUX | SCORE | MOLECULAR-WEIGHT HEPARIN | PLATELET COUNT | RISK | PLATELET-FACTOR-4 | Thrombocytopenia | Complications and side effects | Care and treatment | Dosage and administration | Antibiotics | Endocarditis | Platelet factor 4 | Immunoglobulins | Warfarin | Side effects | Bacterial infections | Immunoglobulin G | Surgery | Heparin | Platelets | Thrombosis
ANTIBODIES | MEDICINE, GENERAL & INTERNAL | IN-VITRO | ACTIVATION | CONFORMATIONAL-CHANGES | FONDAPARINUX | SCORE | MOLECULAR-WEIGHT HEPARIN | PLATELET COUNT | RISK | PLATELET-FACTOR-4 | Thrombocytopenia | Complications and side effects | Care and treatment | Dosage and administration | Antibiotics | Endocarditis | Platelet factor 4 | Immunoglobulins | Warfarin | Side effects | Bacterial infections | Immunoglobulin G | Surgery | Heparin | Platelets | Thrombosis
Journal Article
Details
Digital rights
Loading RightsAnnals of Internal Medicine, ISSN 0003-4819, 02/2004, Volume 140, Issue 3, pp. 175 - I43
Background: Low-molecular-weight heparin has greatly simplified the management of deep venous thrombosis. However, for patients who present with pulmonary...
LONG-TERM | MEDICINE, GENERAL & INTERNAL | RECURRENT VENOUS THROMBOEMBOLISM | STANDARD HEPARIN | OUTPATIENT TREATMENT | FRAGMIN | PREVENTION | DEEP-VEIN THROMBOSIS | INITIAL TREATMENT | DAILY SUBCUTANEOUS DALTEPARIN | HOME | Recurrence | Injections, Intravenous | Prospective Studies | Venous Thrombosis - drug therapy | Humans | Mortality | Heparin, Low-Molecular-Weight - adverse effects | Heparin - therapeutic use | Heparin - adverse effects | Venous Thrombosis - complications | Heparin, Low-Molecular-Weight - therapeutic use | Randomized Controlled Trials as Topic | Injections, Subcutaneous | Sensitivity and Specificity | Pulmonary Embolism - drug therapy | Hemorrhage - chemically induced | Pulmonary embolism | Care and treatment | Dosage and administration | Research | Heparin | Meta-analysis
LONG-TERM | MEDICINE, GENERAL & INTERNAL | RECURRENT VENOUS THROMBOEMBOLISM | STANDARD HEPARIN | OUTPATIENT TREATMENT | FRAGMIN | PREVENTION | DEEP-VEIN THROMBOSIS | INITIAL TREATMENT | DAILY SUBCUTANEOUS DALTEPARIN | HOME | Recurrence | Injections, Intravenous | Prospective Studies | Venous Thrombosis - drug therapy | Humans | Mortality | Heparin, Low-Molecular-Weight - adverse effects | Heparin - therapeutic use | Heparin - adverse effects | Venous Thrombosis - complications | Heparin, Low-Molecular-Weight - therapeutic use | Randomized Controlled Trials as Topic | Injections, Subcutaneous | Sensitivity and Specificity | Pulmonary Embolism - drug therapy | Hemorrhage - chemically induced | Pulmonary embolism | Care and treatment | Dosage and administration | Research | Heparin | Meta-analysis
Journal Article
Details
Digital rights
Loading RightsJournal of the American College of Cardiology, ISSN 0735-1097, 05/2016, Volume 67, Issue 21, pp. 2519 - 2532
Heparin-induced thrombocytopenia is a profoundly dangerous, potentially lethal, immunologically mediated adverse drug reaction to unfractionated heparin or,...
antithrombin agents | cardiopulmonary bypass | bivalirudin | anticoagulant agents | argatroban | platelets | CARDIAC & CARDIOVASCULAR SYSTEMS | FACTOR 4/HEPARIN ANTIBODIES | CORONARY-ARTERY-BYPASS | CRITICALLY III PATIENTS | CARDIAC-SURGERY | MOLECULAR-WEIGHT HEPARIN | MICROPARTICLE GENERATION ASSAY | OF-THE-LITERATURE | DIRECT THROMBIN INHIBITORS | OPEN-HEART-SURGERY | Polysaccharides - therapeutic use | Recombinant Proteins - therapeutic use | Platelet Transfusion | Antithrombins - therapeutic use | Humans | Pipecolic Acids - pharmacokinetics | Risk Factors | Peptide Fragments - pharmacokinetics | Recombinant Proteins - pharmacokinetics | Thrombocytopenia - chemically induced | Cardiopulmonary Bypass | Anticoagulants - adverse effects | Antithrombins - pharmacokinetics | Heparin - adverse effects | Incidence | Plasmapheresis | Pipecolic Acids - therapeutic use | Platelet Function Tests | Thrombocytopenia - diagnosis | Peptide Fragments - therapeutic use | Thrombocytopenia - therapy | Hirudins - pharmacokinetics | Percutaneous Coronary Intervention | Thrombocytopenia | Transluminal angioplasty | Enzymes | Catheterization | Medical societies | Immunoglobulin G | Thrombin | Thrombosis | Risk factors | Blood clot | Complications and side effects | Coronary artery bypass | Heparin | Enzyme-linked immunosorbent assay | Heart attacks | Blood platelets | Heart surgery | Laboratories | Embolisms | Mortality | Gangrene | Bone surgery | Patients
antithrombin agents | cardiopulmonary bypass | bivalirudin | anticoagulant agents | argatroban | platelets | CARDIAC & CARDIOVASCULAR SYSTEMS | FACTOR 4/HEPARIN ANTIBODIES | CORONARY-ARTERY-BYPASS | CRITICALLY III PATIENTS | CARDIAC-SURGERY | MOLECULAR-WEIGHT HEPARIN | MICROPARTICLE GENERATION ASSAY | OF-THE-LITERATURE | DIRECT THROMBIN INHIBITORS | OPEN-HEART-SURGERY | Polysaccharides - therapeutic use | Recombinant Proteins - therapeutic use | Platelet Transfusion | Antithrombins - therapeutic use | Humans | Pipecolic Acids - pharmacokinetics | Risk Factors | Peptide Fragments - pharmacokinetics | Recombinant Proteins - pharmacokinetics | Thrombocytopenia - chemically induced | Cardiopulmonary Bypass | Anticoagulants - adverse effects | Antithrombins - pharmacokinetics | Heparin - adverse effects | Incidence | Plasmapheresis | Pipecolic Acids - therapeutic use | Platelet Function Tests | Thrombocytopenia - diagnosis | Peptide Fragments - therapeutic use | Thrombocytopenia - therapy | Hirudins - pharmacokinetics | Percutaneous Coronary Intervention | Thrombocytopenia | Transluminal angioplasty | Enzymes | Catheterization | Medical societies | Immunoglobulin G | Thrombin | Thrombosis | Risk factors | Blood clot | Complications and side effects | Coronary artery bypass | Heparin | Enzyme-linked immunosorbent assay | Heart attacks | Blood platelets | Heart surgery | Laboratories | Embolisms | Mortality | Gangrene | Bone surgery | Patients
Journal Article
Details
Digital rights
Loading RightsCochrane Database of Systematic Reviews, ISSN 1469-493X, 04/2017, Volume 2017, Issue 4, p. CD000119
Background Low-molecular-weight heparins (LMWHs) and heparinoids are anticoagulants that may have more powerful antithrombotic effects than standard...
ENOXAPARIN | Fibrinolytic Agents [therapeutic use] | EVENTS | Stroke [drug therapy] | EFFICACY | SAFETY | Humans | PREVENTION | DEEP-VEIN THROMBOSIS | Brain Ischemia [drug therapy] | VENOUS THROMBOEMBOLISM PROPHYLAXIS | Randomized Controlled Trials as Topic | MEDICINE, GENERAL & INTERNAL | Heparinoids [therapeutic use] | PULMONARY-EMBOLISM | Low-Molecular-Weight [therapeutic use] | DOUBLE-BLIND | MEDICAL PATIENTS | Heparin [therapeutic use] | Heparin | Anticoagulants [therapeutic use] | Acute Disease | Hemorrhage - epidemiology | Anticoagulants - therapeutic use | Heparin - therapeutic use | Stroke - drug therapy | Pulmonary Embolism - epidemiology | Heparin, Low-Molecular-Weight - therapeutic use | Cause of Death | Brain Ischemia - drug therapy | Fibrinolytic Agents - therapeutic use | Venous Thrombosis - epidemiology | Heparinoids - therapeutic use | Hemorrhage - chemically induced | Stroke - mortality
ENOXAPARIN | Fibrinolytic Agents [therapeutic use] | EVENTS | Stroke [drug therapy] | EFFICACY | SAFETY | Humans | PREVENTION | DEEP-VEIN THROMBOSIS | Brain Ischemia [drug therapy] | VENOUS THROMBOEMBOLISM PROPHYLAXIS | Randomized Controlled Trials as Topic | MEDICINE, GENERAL & INTERNAL | Heparinoids [therapeutic use] | PULMONARY-EMBOLISM | Low-Molecular-Weight [therapeutic use] | DOUBLE-BLIND | MEDICAL PATIENTS | Heparin [therapeutic use] | Heparin | Anticoagulants [therapeutic use] | Acute Disease | Hemorrhage - epidemiology | Anticoagulants - therapeutic use | Heparin - therapeutic use | Stroke - drug therapy | Pulmonary Embolism - epidemiology | Heparin, Low-Molecular-Weight - therapeutic use | Cause of Death | Brain Ischemia - drug therapy | Fibrinolytic Agents - therapeutic use | Venous Thrombosis - epidemiology | Heparinoids - therapeutic use | Hemorrhage - chemically induced | Stroke - mortality
Journal Article
Details
Digital rights
Loading RightsChest, ISSN 0012-3692, 01/2001, Volume 119, Issue 1, pp. 64S - 94S
CONTINUOUS INTRAVENOUS HEPARIN | PLATELET-DERIVED MICROPARTICLES | LOW-DOSE HEPARIN | RESPIRATORY SYSTEM | FATAL PULMONARY-EMBOLISM | ACUTE MYOCARDIAL-INFARCTION | DEEP-VEIN THROMBOSIS | PATHOLOGISTS CONFERENCE XXXI | PARTIAL THROMBOPLASTIN TIME | ACUTE VENOUS THROMBOEMBOLISM | HISTIDINE-RICH GLYCOPROTEIN | CRITICAL CARE MEDICINE | Heparin, Low-Molecular-Weight - pharmacology | Venous Thrombosis - drug therapy | Humans | Heparin, Low-Molecular-Weight - adverse effects | Anticoagulants - therapeutic use | Heparin - therapeutic use | Anticoagulants - adverse effects | Heparin - adverse effects | Heparin, Low-Molecular-Weight - therapeutic use | Heparin - pharmacokinetics | Heparin, Low-Molecular-Weight - pharmacokinetics | Myocardial Infarction - drug therapy | Angina, Unstable - drug therapy | Anticoagulants - pharmacology | Coronary Disease - drug therapy | Venous Thrombosis - prevention & control | Anticoagulants - pharmacokinetics | Heparin - pharmacology
Journal Article
Details
Digital rights
Loading Rights